JMP reiterates Oscient at market outperform

JMP Securities analyst Michelle Lange reiterated Oscient Pharmaceuticals Corp. at market outperform as the analyst continues to track weekly Factive and Testim prescription volumes using NDC Health data. For the week ending April 28, Factive total prescriptions were 5,847 (5,662 new), or 0.92% of weekly prescriptions for the quinolone class of antibiotics. This compares with 5,466 total prescriptions (5,279 new) in the previous week, or 0.87% of weekly prescriptions from the quinolone class. Through April 28, approximately 22,149 Factive prescriptions have been written in the second quarter generating about $2 million in revenue. Total Testim scripts for the week ending April 28 were 5,574 compared with 5,205 for the previous week. Shares of the Waltham, Mass., biopharmaceutical company were down 8 cents, or 4.71%, at $1.62 on volume of 507,261 shares versus the three-month running average of 440,930 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.